The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed the S&P 500 ETF (SPY) in March and continues to lag in April, reflecting varied performance among individual Dividend Aristocrats. Dividend growth among these Aristocrats remains modest in 2026, averaging a 3.49% increase, slightly up from 3.40% last month. Analysts identified 33 Dividend Aristocrats as potentially undervalued, each offering an estimated long-term annualized return of at least 10%. A custom framework combining dividend yield theory, momentum, and expected return highlights these opportunities but is intended as a starting point for further research, not direct investment advice.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
